AFMD
Price
$1.19
Change
+$0.01 (+0.85%)
Updated
Dec 20 closing price
95 days until earnings call
NTLA
Price
$12.21
Change
+$0.13 (+1.08%)
Updated
Dec 20, 04:59 PM (EDT)
60 days until earnings call
Ad is loading...

AFMD vs NTLA

Header iconAFMD vs NTLA Comparison
Open Charts AFMD vs NTLABanner chart's image
Affimed
Price$1.19
Change+$0.01 (+0.85%)
Volume$419.31K
CapitalizationN/A
Intellia Therapeutics
Price$12.21
Change+$0.13 (+1.08%)
Volume$70.18K
CapitalizationN/A
AFMD vs NTLA Comparison Chart
Loading...
AFMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AFMD vs. NTLA commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AFMD is a Hold and NTLA is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (AFMD: $1.19 vs. NTLA: $12.18)
Brand notoriety: AFMD and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AFMD: 136% vs. NTLA: 129%
Market capitalization -- AFMD: $19.34M vs. NTLA: $1.24B
AFMD [@Biotechnology] is valued at $19.34M. NTLA’s [@Biotechnology] market capitalization is $1.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AFMD’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • AFMD’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than AFMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AFMD’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • AFMD’s TA Score: 4 bullish, 6 bearish.
  • NTLA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than AFMD.

Price Growth

AFMD (@Biotechnology) experienced а -44.65% price change this week, while NTLA (@Biotechnology) price change was -5.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

AFMD is expected to report earnings on Mar 27, 2025.

NTLA is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.24B) has a higher market cap than AFMD($19.3M). NTLA YTD gains are higher at: -60.052 vs. AFMD (-80.960). AFMD has higher annual earnings (EBITDA): -65.19M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. AFMD (24.9M). AFMD has less debt than NTLA: AFMD (12.9M) vs NTLA (102M). NTLA has higher revenues than AFMD: NTLA (43.1M) vs AFMD (877K).
AFMDNTLAAFMD / NTLA
Capitalization19.3M1.24B2%
EBITDA-65.19M-527.52M12%
Gain YTD-80.960-60.052135%
P/E RatioN/AN/A-
Revenue877K43.1M2%
Total Cash24.9M658M4%
Total Debt12.9M102M13%
FUNDAMENTALS RATINGS
AFMD vs NTLA: Fundamental Ratings
AFMD
NTLA
OUTLOOK RATING
1..100
5173
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
9891
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (30) in the Biotechnology industry is somewhat better than the same rating for AFMD (71). This means that NTLA’s stock grew somewhat faster than AFMD’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AFMD (100). This means that NTLA’s stock grew similarly to AFMD’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as AFMD (98). This means that NTLA’s stock grew similarly to AFMD’s over the last 12 months.

NTLA's Price Growth Rating (91) in the Biotechnology industry is in the same range as AFMD (98). This means that NTLA’s stock grew similarly to AFMD’s over the last 12 months.

AFMD's P/E Growth Rating (95) in the Biotechnology industry is in the same range as NTLA (100). This means that AFMD’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AFMDNTLA
RSI
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 14 days ago
81%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
AFMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEOHX18.670.20
+1.08%
Voya Large Cap Growth Port I
EIEAX36.520.37
+1.02%
Eaton Vance Tax-Managed Eq Aset Allc I
SUHCX22.260.12
+0.54%
DWS Health and Wellness C
MRSJX22.37-0.04
-0.18%
MFS Research International R4
FPCGX25.03-4.69
-15.77%
Fort Pitt Capital Total Return

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+0.83%
VCYT - NTLA
69%
Closely correlated
+4.66%
EDIT - NTLA
68%
Closely correlated
-2.24%
BEAM - NTLA
66%
Loosely correlated
+8.04%
CRSP - NTLA
62%
Loosely correlated
+0.83%
PRME - NTLA
59%
Loosely correlated
+3.94%
More